Oxford Biomedica/£OXB
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Oxford Biomedica
Ticker
£OXB
Sector
Primary listing
LSE
Industry
Biotechnology
Headquarters
Employees
850
ISIN
GB00BDFBVT43
Website
Oxford Biomedica Metrics
BasicAdvanced
£385M
-
-£0.42
0.96
-
Price and volume
Market cap
£385M
Beta
0.96
52-week high
£3.72
52-week low
£3.48
Financial strength
Current ratio
2.284
Quick ratio
1.983
Long term debt to equity
172.502
Total debt to equity
179.809
Interest coverage (TTM)
-3.84%
Profitability
EBITDA (TTM)
-22.387
Gross margin (TTM)
41.17%
Net profit margin (TTM)
-33.53%
Operating margin (TTM)
-29.35%
Effective tax rate (TTM)
-2.84%
Revenue per employee (TTM)
£150,000
Management effectiveness
Return on assets (TTM)
-10.15%
Return on equity (TTM)
-70.28%
Valuation
Price to revenue (TTM)
2.974
Price to book
6.73
Price to tangible book (TTM)
13.8
Price to free cash flow (TTM)
-6.586
Free cash flow yield (TTM)
-15.18%
Free cash flow per share (TTM)
-56.22%
Growth
Revenue change (TTM)
43.84%
Earnings per share change (TTM)
-74.41%
3-year revenue growth (CAGR)
-3.38%
10-year revenue growth (CAGR)
25.19%
3-year earnings per share growth (CAGR)
23.43%
10-year earnings per share growth (CAGR)
6.89%
What the Analysts think about Oxford Biomedica
Analyst ratings (Buy, Hold, Sell) for Oxford Biomedica stock.
Bulls say / Bears say
Oxford Biomedica's rebranding to OXB in September 2024 underscores its transformation into a global pure-play cell and gene therapy CDMO, potentially enhancing its market presence and client engagement. (biospace.com)
The acquisition of the remaining 10% stake in its US subsidiary in March 2025 strengthens OXB's position in the expanding viral vector manufacturing market, providing full control over its Bedford, Massachusetts facility. (sharesmagazine.co.uk)
OXB's expansion of its License and Supply Agreement with Cabaletta Bio in August 2023 reflects its commitment to quality and innovation, potentially leading to increased revenue streams from milestone payments and royalties. (insidermedia.com)
Despite strong revenue growth, OXB reported a low double-digit Operating EBITDA loss for the full year 2024, indicating ongoing profitability challenges. (globenewswire.com)
The integration of ABL Europe, acquired in September 2023, may present operational challenges and potential financial strain during the transition period. (wikipedia.org)
OXB's reliance on a limited number of key clients for a significant portion of its revenue could pose risks if any major client reduces or terminates their contracts. (sharesmagazine.co.uk)
Data summarised monthly by Lightyear AI. Last updated on 15 Jul 2025.
Oxford Biomedica Financial Performance
Revenues and expenses
Oxford Biomedica Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oxford Biomedica stock?
Oxford Biomedica (OXB) has a market cap of £385M as of July 18, 2025.
What is the P/E ratio for Oxford Biomedica stock?
The price to earnings (P/E) ratio for Oxford Biomedica (OXB) stock is 0 as of July 18, 2025.
Does Oxford Biomedica stock pay dividends?
No, Oxford Biomedica (OXB) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Oxford Biomedica dividend payment date?
Oxford Biomedica (OXB) stock does not pay dividends to its shareholders.
What is the beta indicator for Oxford Biomedica?
Oxford Biomedica (OXB) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.